Actelion Lung Drug Meets Main Goal in Pivotal Patient Study

Actelion Ltd. (ATLN)’s experimental lung drug macitentan met the main goal of a late-stage clinical trial, providing the company with a possible successor to a treatment that accounts for 89 percent of sales. Patients with pulmonary arterial hypertension given 10- milligram doses of macitentan were 45 percent less likely to experience a worsening of disease than those who got a placebo, the Allschwil, Switzerland-based company said in a statement today. Those who got 3-milligram doses in the so-called Seraphin study of 742 people were 30 percent less likely. The results bolster Chief Executive Officer Jean-Paul Clozel, who said last year that macitentan’s prospects justified keeping Actelion…

WN.com – Health News